Table 1.
Comparison of the LEN-TACE and LEN monotherapy groups in the unmatched and propensity score-matched cohorts
| Characteristics | Unmatched cohort |
Propensity score-matched cohort |
||||
|---|---|---|---|---|---|---|
| LEN-TACE (n = 63) | LEN monotherapy (n = 167) | p value | LEN-TACE (n = 63) | LEN monotherapy (n = 63) | p value | |
| Gender, males/females | 51/12 | 139/28 | 0.684 | 51/12 | 53/10 | 0.639 |
| Age, years | 70.4±9.6 | 71.2±8.3 | 0.621 | 70.4±9.6 | 69.6±8.9 | 0.597 |
| BMI, kg/m2 | 23.7 (21.1–27.3) | 23.4 (21.2–25.6) | 0.887 | 23.7 (21.1–27.3) | 23.9 (22.2–27.4) | 0.973 |
| Etiology, HBV/HCV/nonviral | 11/19/33 | 40/47/80 | 0.571 | 11/19/33 | 15/17/31 | 0.673 |
| ECOG PS, 0/1 | 53/10 | 136/31 | 0.717 | 53/10 | 52/11 | 0.811 |
| Naive/non-naive | 16/47 | 30/137 | 0.209 | 16/47 | 15/48 | 0.836 |
| History of TKI treatment, n (%) | 2 (3.2) | 33 (19.6) | 0.002 | 2 (3.2) | 2 (3.2) | 1.000 |
| TACE refractoriness, n (%) | 22 (34.9) | 47 (27.9) | 0.317 | 22 (34.9) | 20 (31.7) | 0.705 |
| mALBI, 1/2a/2b | 24/14/25 | 65/48/68 | 0.897 | 24/14/25 | 21/10/21 | 0.910 |
| Child-Pugh score, 5/6/7 (points) | 36/20/7 | 101/50/16 | 0.812 | 36/20/7 | 39/18/6 | 0.860 |
| Tumor size, mm | 5.0 (3.5–7.6) | 4.8 (3.0–9.0) | 0.377 | 5.0 (3.5–7.6) | 4.9 (3.2–7.0) | 0.872 |
| Tumors, n single/multiple | 20/43 | 42/125 | 0.315 | 20/43 | 23/40 | 0.573 |
| MVI, Vp0/1/2/3/4 | 35/13/10/4/1 | 101/17/35/11/3 | 0.326 | 35/13/10/4/1 | 43/4/12/4/0 | 0.149 |
| EM, n (%) | 16 (25.3) | 51 (30.5) | 0.444 | 16 (25.3) | 17 (26.9) | 0.839 |
| BCLC stage, B/C | 27/36 | 66/101 | 0.649 | 27/36 | 32/31 | 0.372 |
| AFP,≥200/<200ng/mL | 21/42 | 60/107 | 0.713 | 21/42 | 23/40 | 0.709 |
| Initial dose of LEN, 8/12 mg | 37/26 | 111/56 | 0.275 | 37/26 | 34/29 | 0.590 |
| RDI,% | 59.4 (40.2–74.8) | 62.4 (37.2–89.8) | 0.829 | 59.4 (40.2–74.8) | 59.6 (35.5–88.1) | 0.881 |
| mRECIST (LEN 8 weeks), CR/PR/SD/PD | 0/35/17/11 | 1/53/57/56 | 0.008 | 0/35/17/11 | 0/35/16/12 | 0.964 |
| RECIST 1.1 (LEN 8 weeks), CR/PR/SD/PD | 0/22/30/11 | 0/28/84/55 | 0.004 | 0/22/30/11 | 0/21/30/12 | 0.967 |
LEN, lenvatinib; TACE, transarterial chemoembolization; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; Non-Viral, non-HBV and non-HCV; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TKI, tyrosine kinase inhibitor; mALBI, modified albumin-bilirubin; MVI, microvascular invasion; Vp, portal vein invasion; EM, extrahepatic metastasis; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; RDI, relative dose intensity; mRECIST, modified Response Evaluation Criteria in Solid Tumors; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. The values represent the mean±standard deviation, median (25th-75th percentile), or patients, n.